[PDF] BRINGING CANCER DISCOVERIES TO PATIENTS

View - Download BRINGING CANCER DISCOVERIES TO PATIENTS

Previous PDF

Next PDF

AACR.org/AnnualReport15

DON ATE

2015 ANNUAL REPORT

BRINGING CANCER DISCOVERIES TO PATIENTS

On the cover (left to right):

Top row

JOSÉ BASELGA, MD, PHD, FAACR

The AACR President for 2015-2016, Dr. Baselga

is Physician-in-Chief at Memorial Sloan Kettering

Cancer Center, New York, New York.

CARLOS L. ARTEAGA, MD, FAACR

The AACR President for 2014-2015, Dr. Arteaga is

Director of the Center for Cancer Targeted Therapies and the Breast Program and SPORE at

Vanderbilt-

Ingram Cancer Center, Nashville, Tennessee.

Bottom row

SERGIO RAMIREZ

Diagnosed with acute lymphoblastic leukemia,

Sergio participated in a clinical trial and is beating the disease thanks to the immunotherapeutic blinatumomab.

JAMEISHA BROWN

Diagnosed with cancer at the age of eight, Jameisha has been cancer-free for 17 years and now conducts research on cancer health disparities.

LORI CUFFARI

Since starting lenvatinib, Lori"s Hurthle cell cancer is no longer visible and she is living a normal life, eating what she wants, and looking forward to the future. AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015 1CONTENTS

MISSION AND VISION

1

WELCOME: BRINGING CANCER DISCOVERIES TO PATIENTS

2

PROGRESS AGAINST CANCER IN 2015

4

ANNUAL MEETING

6

AACR INTERNATIONAL

12

HONORING SCIENTIFIC ACHIEVEMENT

14

SCIENTIFIC PUBLISHING

18

SCIENCE AND EDUCATION

22

SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION

28
GOVERNMENT AFFAIRS / SURVIVOR AND PATIENT ADVOCACY 32

MEMBERSHIP

36

LEADERSHIP

40

AACR FOUNDATION

46

FINANCIAL STATEMENT

56

THE AACR IN 2016: A LOOK AHEAD

58
Follow us: AACR.orgDONATE

MISSION

?e mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through research, education, communication, and collaboration. ?rough its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research ndings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.VISION

To be the most eective catalyst for cures

and prevention through cancer science.

HISTORY

?e AACR is the world"s rst and largest cancer research organization dedicated to accelerating the prevention and cure of cancer. Founded in 1907 by nine physicians and two laboratory scientists, the AACR has more than 35,000 members in 101 countries. Learn more about the history of the AACR at

AACR.org/history

.Immuno?uorescence confocal microscopy image of an immunostained whole mount preparation of the dorsal mouse ear dermis. Swartz, M.A.

Cancer

Immunology Research

August 2014 2:701-707.

AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015 32 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015

WELCOME

BRINGING CANCER DISCOVERIES TO PATIENTS

We are pleased to

present the 2015

Annual Report of the

American Association

for Cancer Research (AACR). The report highlights the AACR"s progress over the past year in support of our mission: to prevent and cure cancer through research, education, communication, and collaboration. ?e theme of the AACR Annual Meeting

2015, "Bringing Cancer Discoveries to

Patients," is also the theme of this report. It

emphasizes the critical value of each step along the cancer science continuum, from basic discoveries to translational advances to clinical treatments. With 35,000 members working in every discipline along that continuum, the AACR is uniquely positioned to improve the lives of cancer patients in a myriad of ways:

Research

?e AACR identi?es and fosters innovative science that is of the highest priority for impact in reducing cancer incidence, morbidity, and mortality. One of the AACR's major mechanisms for accomplishing this goal is to promote high-quality science through its Scienti?c

Review and Grants Administration

program. ?e AACR provides scienti?c oversight and expert peer review to ensure that the most promising projects receive essential funding. Working with funding partners throughout the cancer community, the AACR awarded nearly $70 million in grants to exceptional investigators in

2015. ?e AACR also fosters innovation

and recognizes the meritorious work of investigators and their impact on the ?eld through Scienti?c Achievement Awards and election as Fellows of the AACR Academy.

Education

?e AACR sustains the pipeline of cancer scientists at all career levels. Special programs inspire high school students and undergraduates to pursue careers in cancer research, and educational workshops teach early-career scientists to become leaders in their ?elds. AACR Annual Meetings and conferences bring together emerging and established scientists to share their research ?ndings and learn about the latest developments in all disciplines. ?e AACR also educates advocates through its highly regarded Scientist

Survivor Program,

pairing them with mentors who provide the scienti?c context for their vitally important work in the cancer ?eld.

Communication

?e AACR's scienti?c journals and conferences provide leading investigators with a vital forum for sharing the latest discoveries, using the page and the podium to disseminate cutting-edge cancer science in all disciplines. ?e AACR also fosters dialogue among the various stakeholders in the cancer community. ?rough brie?ngs, workshops, and the AACR Cancer Progress

Report, the O?ce of Science Policy and

Government A?airs keeps lawmakers,

regulators, and the public informed about the critical value of cancer research. In addition, Cancer Today magazine and the Survivor and Patient Advocacy program provide authoritative knowledge that empowers patients, caregivers, and patient advocates to meet the challenges of a cancer diagnosis.

Collaboration

With members in 101 countries and a

longstanding reputation for scienti?c excellence, the AACR forges partnerships with scienti?c and advocacy organizations worldwide to advance science for the bene?t of all cancer patients. In addition, the AACR's cross-disciplinary meetings, workshops, and task forces bring investigators from academia, government, and industry together, breaking down silos and building productive relationships.

Cancer is a complex disease, and achieving

our mission to prevent and cure all cancers requires a concerted e?ort in a wide range of scienti?c and policy areas.

As this report demonstrates, the AACR is

actively engaged in these areas, supporting the community that will translate our increasing understanding of the cancer problem into solutions. OUR MISSION IS AMBITIOUS. TOGETHER, WE WILL ACHIEVE IT.

Le to right:

José Baselga, MD, PhD, FAACR

AACR President 2015-2016

Margaret Foti, PhD, MD (hc)

AACR Chief Executive Ocer

Carlos L. Arteaga, MD, FAACR

AACR President 2014-2015

AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015 3

AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015 54 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015

PROGRESS AGAINST CANCER IN 2015

POWERED BY RESEARCH

Research increases understanding of the collection of diseases known as cancer and allows the translation of knowledge into new and increasingly precise ways to prevent, detect, diagnose, treat, and cure many of these diseases. In 2015 alone, research fueled U.S. Food and Drug Administration (FDA) approval of 16 new anticancer therapeutics and seven new uses for previously approved anticancer therapeutics.

Nine of the newly approved drugs —

alectinib (Alecensa), cobimetinib (Cotelli), daratumumab (Darzalex), elotuzumab (Empliciti), lenvatinib (Lenvima), necitumumab (Portrazza), osimertinib (Tagrisso), palbociclib (Ibrance), and sonidegib (Odomzo) — target speci?c molecules involved in cancer and are referred to as molecularly targeted therapeutics. ?ey are part of the precision medicine revolution that is ensuring that more people are living longer, higher- quality lives aer a cancer diagnosis.

Four of the newly approved drugs —

daratumumab (Darzalex), dinutixumab (Unituxin), elotuzumab, and talimogene laherparepvec (Imlygic) — work by harnessing the power of a patient's own immune system to ?ght his or her cancer, which demonstrates the emergence of cancer immunotherapy as a key pillar of care. ?e power of cancer immunotherapy lies in the remarkable and durable responses experienced by patients with a variety of types of cancer. ?e American Association for Cancer

Research (AACR) is proud to have helped

catalyze the progress made against cancer in

2015 through its many programs, services,

and initiatives. For example, early results from the clinical trial that led to the October 2015

FDA approval of the immunotherapeutic

pembrolizumab (Keytruda) for treating certain patients with non-small cell lung cancer were ?rst disseminated at the AACR Annual Meeting 2015.With one in two men and one in three women in the U.S. expected to be diagnosed with cancer in their lifetimes, it is vital that the AACR communicates the spectacular advances against cancer to all sectors of the American population. ?e annual AACR Cancer Progress Report is a cornerstone of the AACR's e?orts to increase public understanding of cancer and the importance of cancer research to public health, and to advocate for increased federal funding for the National Institutes of Health (NIH), the National Cancer

Institute (NCI), and the FDA.

?e

AACR Cancer Progress Report 2015

chronicles how federally funded research spurred progress against cancer in 2015 and showcases the fact that the number of FDA- approved molecularly targeted anticancer therapeutics more than doubled in the past ?ve years.

As AACR President (2015-2016) José

Baselga, MD, PhD, FAACR, stated in the

report, "...these are exciting times and... the pace of discovery and application of new knowledge to patient care is rapidly accelerating." ...these are exciting times and...the pace of discovery and application of new knowledge to patient care is rapidly accelerating. - José Baselga, MD, PhD, FAACR

Right: Survivors featured in the

AACR Cancer

Progress Report 2015

. e annual AACR Cancer

Progress Report is a cornerstone of the AACR"s

eorts to increase public understanding of cancer and the importance of cancer research to public health, and to advocate for increased federal

funding for cancer research.Renata Pasqualini, PhD (right) and her husband Wadih Arap, MD, PhD (le) in their joint laboratory at the University of New Mexico Comprehensive Cancer Center. An AACR Career Development Grantee, Dr. Pasqualini was motivated to pursue a career in medical research by her mother"s breast cancer diagnosis and successful treatment.

AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015 5

AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015 76 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL REPORT 2015

ANNUAL MEETING

CROSSROADS OF THE CANCER COMMUNITY

All of the stakeholders

in cancer research come together at the

AACR Annual Meeting.

The 2015 Annual

quotesdbs_dbs46.pdfusesText_46

[PDF] 2015 washington state energy code forms

[PDF] 2015 washington wild things schedule

[PDF] 2015-14

[PDF] 2015-17 movies

[PDF] 2015-54

[PDF] 2016 10k across the bay

[PDF] 2016 2nd avenue north birmingham alabama

[PDF] 2016 2nd presidential debate

[PDF] 2016 2nd round draft order

[PDF] 2016 3.5 ecoboost problems

[PDF] 2016 6.2 ford engine specs

[PDF] 2016 6.7 cummins performance

[PDF] 2016 6.7 powerstroke problems

[PDF] 2016 6.7 powerstroke reviews

[PDF] 2016 7 mile bridge run results